ANNEXON BIOSCIENCES

Serial Number 98694167
688

Registration Progress

Application Filed
Aug 12, 2024
Under Examination
May 13, 2025
Approved for Publication
Mar 18, 2025
Published for Opposition
Mar 18, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Nov 13, 2025 101 days

Trademark Image

ANNEXON BIOSCIENCES

Basic Information

Serial Number
98694167
Filing Date
August 12, 2024
Published for Opposition
March 18, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
May 13, 2025
Application
Pending
Classes
005 042 044

Rights Holder

Annexon, Inc.

03
Address
1400 Sierra Point Pkwy., Bldg. C, 2nd Fl
Brisbane, CA 94005

Ownership History

Annexon, Inc.

Original Applicant
03
Brisbane, CA

Annexon, Inc.

Owner at Publication
03
Brisbane, CA

Legal Representation

Attorney
Joshua S. Jarvis, Esq.

USPTO Deadlines

Next Deadline
101 days remaining
NOA E-Mailed - SOU Required
Due Date
November 13, 2025
Extension Available
Until May 13, 2026

Application History

12 events
Date Code Type Description Documents
May 13, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 18, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 18, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 12, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 20, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 20, 2025 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Feb 20, 2025 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Feb 20, 2025 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Feb 20, 2025 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Feb 19, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 16, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 12, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG).
Class 042
Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
Class 044
Providing medical information; providing medical information related to pharmaceuticals.

Classification

International Classes
005 042 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCES"